Initially purported hepatotoxicity by Pelargonium sidoides: The dilemma of pharmacovigilance and proposals for improvement

Annals of Hepatology

Volumn 11, Issue 4, 2012, Pages 500-512

  Teschke, Rolf ^a   Frenzel, Christian ^b   Wolff, Albrecht ^c   Herzog, Jutta ^a   Glass, Xaver ^d   Schulze, Johannes ^d   Eickhoff, Axel ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^c FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^d GOETHE UNIVERSITY MEDICAL SCHOOL   (Germany)

Author keywords

Herb induced liver injury; Herbal hepatotoxicity; Pelargonium sidoides; Pelargonium sidoides questionable hepatotoxicity; Pharmacovigilance

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ANTINUCLEAR ANTIBODY; ASPARTATE AMINOTRANSFERASE; HERBACEOUS AGENT; INFLIXIMAB; NONSTEROID ANTIINFLAMMATORY AGENT; OLMESARTAN; PREDNISONE; PLANT EXTRACT; RESPIRATORY TRACT AGENT;

ABNORMAL LABORATORY RESULT; ACUTE CHOLECYSTITIS; ACUTE PANCREATITIS; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; AUTOIMMUNE HEPATITIS; BACTERIAL INFECTION; BRONCHITIS; CHOLANGITIS; CHRONIC SINUSITIS; CLINICAL ARTICLE; COMORBIDITY; COUGHING; COUNCIL FOR INTERNATIONAL ORGANIZATIONS OF MEDICAL SCIENCES SCALE; DATA ANALYSIS; DRUG OVERDOSE; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; FEMALE; FLU LIKE SYNDROME; HEPATITIS; HUMAN; INFECTION; LIVER TOXICITY; LUNG CONTUSION; MALE; MEDICAL SPECIALIST; OUTCOME ASSESSMENT; PELARGONIUM; PELARGONIUM SIDOIDES; PHARYNGITIS; PNEUMOTHORAX; POLYPHARMACY; QUALITY CONTROL; QUANTITATIVE ANALYSIS; RATING SCALE; RECOMMENDED DRUG DOSE; RHINOPHARYNGITIS; RISK ASSESSMENT; SINUBRONCHITIS; SINUSITIS; TOXIC HEPATITIS; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION; VIRUS INFECTION; HERB DRUG INTERACTION; MIDDLE AGED; PATIENT SAFETY; PLANT ROOT; RISK FACTOR;

ADULT; ADVERSE DRUG REACTION REPORTING SYSTEMS; AGED; AGED, 80 AND OVER; COMORBIDITY; DRUG-INDUCED LIVER INJURY; FEMALE; HERB-DRUG INTERACTIONS; HUMANS; MALE; MIDDLE AGED; PATIENT SAFETY; PELARGONIUM; PHARMACOVIGILANCE; PLANT EXTRACTS; PLANT ROOTS; RESPIRATORY SYSTEM AGENTS; RISK ASSESSMENT; RISK FACTORS;

EID: 84861998435     PISSN: 16652681     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1665-2681(19)31464-4     Document Type: Article

References (45)

1. Aronson JK. Adverse drug reactions: History, terminology, classification, causality, frequency, preventability. In: Talbot J, Aronson JK. Stephens' detection and evaluation of adverse drug reactions: principles and practice. 6th. Ed. John Wiley & Sons, Ltd.; 2011. DOI: 10.1002/9780470975053. ch1.
2. Lynn E, Layton D, Shakir S. New postgraduate qualifications in pharmacovigilance from the Drug Safety Research Unit in the UK. Drug Saf 2011; 34: 89-91.
3. Kelly WN, Arellano FM, Barnes J, Bergman U, Edwards RI, Fernandez AM, Freedman SB, et al; International Society for Pharmacoepidemiology; International Society for Pharmacovigilance. Guidelines for submitting adverse events reports for publication. Drug Saf 2007; 30: 367-73.
4. Impicciatore P, Mucci M. Completeness of published case reports on suspected adverse drug reactions. Drug Saf 2010; 30: 765-73.
5. Agarwal VK, McHutchison JG, Hoofnagle JH, Drug-Induced Liver Injury Network (DILIN). Important elements for the diagnosis of drug-induced liver injury. Clin Gastroenterol Hepatol 2010; 8: 463-70.
6. Hung SK, Hillier S, Ernst E. Case reports of adverse effect of herbal medical products (HMPs): A quality assessment. Phytomedicine 2011; 18: 335-43.
7. Teschke R. Hepatotoxicity by drugs and dietary supplements: safety perspectives on clinical and regulatory issues. Ann Hepatol 2009; 8: 184-95.
8. Garcia-Cortés M, Stephens C, Lucena MI, Fernández Castañer A, Andrade RJ; On behalf of the Spanish Group for the Study of Drug-Induced Liver Disease. Causality assessment methods in drug induced liver injury: Strengths and weaknesses. J Hepatol 2011; 55: 683-91.
9. Teschke R, Bahre R, Genthner A, Fuchs J, Schmidt-Taenzer W, Wolff A. Suspected black cohosh hepatotoxicity-Causality assessment versus safety signal. Quality versus quantity. Maturitas 2009; 64: 141-42.
10. EMA (European Medicines Agency). Assessment report on Pelargonium sidoides DC and/or Pelargonium reniforme Curt., radix. Available at: http://www.ema.europa.eu/ docs/en_GB/document_library/Herbal_HMPC_assessment_report/2011 /06lWC500107717. pdf [Issued March 31, 2011; accessed February 20, 2012].
11. Drug Commission of the German Medical Association (Arz neimittelkommission der Deutschen Arzteschaft). Hepatitis in connection with Umckaloabo®. Deutsches Arzteblatt 2011; 108: C1399-C1400 (article in German).
12. Teschke R, Frenzel C, Schulze J, Eickhoff A. Spontaneous reports of primarily suspected herbal hepatotoxicity by Pelargonium sidoides: was causality adequately ascertained? Regul Toxicol Pharmacol 2012; 63: 1-9.
13. Danan G, Bénichou C. Causality assessment of adverse reactions to drugs-I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol 1993; 46: 1323-30.
14. Bénichou C, Danan G, Flahault A. Causality assessment of adverse reactions to drugs-II. An original model for validation of drug causality assessment methods: case reports with positive rechallenge. J Clin Epidemiol 1993; 46: 1331-6.
15. Teschke R, Schwarzenboeck A, Hennermann KH. Causality assessment in hepatotoxicity by drugs and dietary supplements. Br J Clin Pharmacol 2008; 66: 758-66.
16. Teschke R, Schmidt-Taenzer W, Wolff A. USP suspected herbal hepatotoxicity: Quality of causality assessment is more important than quantity of counted cases, not vice versa. Pharmacoepidemiol Drug Saf 2012; 21: 336-338.
17. Teschke R, Schulze J. Suspected herbal hepatotoxicity: Requirements for appropriate causality assessment by the US Pharmacopeia. Drug Saf 2012 [In press].
18. Daniele C, Thompson Coon J, Pittler MH, Ernst E. Vitex agnus castus: A systematic review of adverse events. Drug Saf 2005; 28: 319-32.
19. Borrelli F, Ernst E. Black cohosh (Cimicifuga racemosa): a systematic review of adverse events. Am J Obstet Gynecol 2008; 199: 455-66.
20. Chan TYK. Potential risks associated with the use of herbal anti-obesity products. Drug Saf 2009; 32: 453-6.
21. Agbabiaka TB, Pittler MH, Wider B, Ernst E. Serenoa repens (Saw Palmetto): A systematic review of adverse events. Drug Saf 2009; 3: 637-47.
22. Saokaew S, Suwankesawong W, Permsuwan U, Chaiyakunapruk N. Safety of herbal products in Thailand: An analysis of reports in the Thai Health Product Vigilance Center Database from 2000 to 2008. Drug Saf 2011; 34: 339-50.
23. Seeff KB. Herbal hepatotoxicity. Clin Liv Dis 2007; 11: 577-96.
24. Shaw D. Pilot case control study of Chinese herbs and liver toxicity. Drug Saf 2008; 31: 885-960.
25. Navarro VJ. Herbal and dietary supplement hepatotoxici ty. Semin Liver Dis 2009; 29: 373-82.
26. Liss G, Lewis JH. Drug-induced liver injury: what was new in 2008? Expert Opin Drug Metab Toxicol 2009; 5: 843-60.
27. Teschke R, Schmidt-Taenzer W, Wolff A. Spontaneous reports of assumed herbal hepatotoxicity by black cohosh: Is the liver unspecific Naranjo scale precise enough to as-certain causality? Pharmacoepidemiol Drug Saf 2011; 20: 567-82.
28. Teschke R, Schwarzenboeck A, Schmidt-Taenzer W, Wolff A, Hennermann KH. Herb induced liver injury presumably caused by black cohosh: A survey of initially purported cases and herbal quality specifications. Ann Hepatol 2011; 11: 249-59.
29. Teschke R, Schwarzenboeck A, Hennermann KH. Kava hepatotoxicity: a clinical survey and critical analysis of 26 suspected cases. Eur J Gastroenterol Hepatol 2008; 20: 1182-93.
30. Teschke R. Kava hepatotoxicity-a clinical review. Ann Hepatol 2010; 9: 251-65.
31. Teschke R, Glass X, Schulze J. Herbal hepatotoxicity by Greater Celandine (Chelidonium majus): Causality assessment of 22 spontaneous reports. Regul Toxicol Pharmacol 2011; 61: 282-91.
32. Teschke R, Glass X, Schulze J, Eickhoff A. Suspected Greater Celandine hepatotoxicity: Liver specific causality evaluation of published case reports from Europe. Eur Gastroenterol Hepatol 2012; 24: 270-80.
33. Aithal GP, Rawlins MD, Day CP. Accuracy of hepatic adverse drug reaction reporting in one English health region. Br Med J 1999; 319: 1541.
34. Aithal PG, Day CP. The natural history of histologically proved drug induced liver disease. Gut 1999; 44: 731-5.
35. Lucena MI, Camargo R, Andrade RJ, Perez-Sanchez CJ, Sanches de la Cuesta F. Comparison of two clinical scales for causality assessment in hepatotoxicity. Hepatology 2001; 33: 123-30.
36. Andrade RJ, Lucena MI, Fernández MC, Pelaez G, Pachkoria K, García Ruiz E, García Muñoz B, et al; Spanish Group for the Study of Drug induced Liver Disease. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10 year period. Gastroenterology 2005: 129: 512-21.
37. Dalton HR, Fellows HJ, Stableforth W, Joseph M, Thurairajah PH, Warshow U, et al. The role of hepatitis E virus testing in drug induced liver injury. Aliment Pharmacol Ther 2007; 26: 1429-35.
38. Davern TJ, Chalasani N, Fontana RJ, Hayashi PH, Protiva P, Kleiner DE, Engle RE, et al; For the Drug Induced Liver Injury Network (DILIN). Acute hepatitis E infection accounts for some cases of suspected drug induced liver injury. Gastroenterology 2011; 141: 1665-72.
39. Teschke R, Schwarzenboeck A. Suspected hepatotoxicity by Cimicifuga racemosa rhizoma (black cohosh, root): Critical analysis and structured causality assessment. Phyto medicine 2009; 16: 72-84.
40. Teschke R, Bahre R, Fuchs J, Wolff A. Black cohosh hepatotoxicity: quantitative causality evaluation in nine suspected cases. Menopause 2009; 16: 956-65.
41. Teschke R, Bahre R, Genthner A, Fuchs J, Schmidt-Taenzer W, Wolff W. Suspected black cohosh hepatotoxicity Challenges and pitfalls of causality assessment. Maturitas 2009; 63: 302-14.
42. Teschke R. Black cohosh and suspected hepatotoxicity-inconsistencies, confounding variables, and prospective use of a diagnostic causality algorithm: A critical review. Menopause 2010; 17: 426-40.
43. Teschke R, Wolff A. Regulatory causality evaluation methods applied in kava hepatotoxicity: Are they appropriate? Regul Toxicol Pharmacol 2011; 59: 1-7.
44. WHO. Causality assessment of suspected adverse reactions. WHO Collaboratoring Centre for International Drug Monitoring (Uppsala Monitoring Centre, UMC), Database. Available at: www.who-umc.org/DynPage.aspx?id=22682 [Accessed February 20, 2012].
45. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, Janecek E, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30: 239-45.